Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Rachel Soon, 04 Aug 2017

Investment in health crisis response systems during non-pandemic periods is crucial to combating the next inevitable flu pandemic, according to a government representative.

30 Apr 2016
New drug applications approved by US FDA as of 16 - 30 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
15 Jan 2017
New drug applications approved by US FDA as of 1 - 15 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

SLP detects tidal breathing patterns like traditional measurement techniques

12 Jan 2017

Structured light plethysmography (SLP), a noncontact, light-based technique, can detect different breathing patterns similar to traditional techniques in patients with chronic obstructive pulmonary disease (COPD) compared with those without any respiratory disease, a study has found.

There have been reported differences in tidal (quiet) breathing patterns between patients with COPD and healthy individuals using traditional measurement techniques, according to researchers who examined whether SLP could also detect differences in tidal breathing patterns between healthy individuals and COPD patients.

The authors recorded a 5-min period of tidal breathing in each COPD patients (n=31) and each healthy participant (n=31), matched for age, body mass index and sex. They calculated the median and interquartile (IQR; denoting within-subject variability) of 12 tidal breathing parameters for every participant, combined individual data by cohort, and summarized these by its median and IQR.

COPD patients had lower inspiratory time (median tI) and variability (IQR of tI) after correction for multiple comparisons (p<0.001 and p<0.01, respectively), as well as ratios derived from tI (tI/tE and tI/tTot; both p<0.01) and their variability (p<0.01 and p<0.05, respectively).

The COPD group also had higher (p<0.001) IE50SLP (the ratio of inspiratory to expiratory flow at 50 percent tidal volume calculated from the SLP signal), but shorter (p<0.01) and considerably less variable (p<0.001) SLP-derived time to reach peak tidal expiratory flow over expiratory time (median tPTEFSLP/tE). Additionally, thoraco-abdominal asynchrony was elevated (p<0.05) in COPD.

The finding provides support for “further investigation into the potential uses of SLP in assessing clinical conditions and interventions,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Rachel Soon, 04 Aug 2017

Investment in health crisis response systems during non-pandemic periods is crucial to combating the next inevitable flu pandemic, according to a government representative.

30 Apr 2016
New drug applications approved by US FDA as of 16 - 30 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
15 Jan 2017
New drug applications approved by US FDA as of 1 - 15 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.